Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment

Abstract

Glaucoma is the leading cause of irreversible blindness. Early diagnosis and effective treatment can reduce the progression of the disease and prevent irreversible decay of visual functions. Indeed, human carboanhydrase isoform II is a classical target for glaucoma treatment. We proposed a compound molecule 5 (5 trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide under the project name B016, which showed high activity as a human carboanhydrase II inhibitor by in vitro tests. Our team is currently conducting development and preclinical studies of a medicinal product in the eye drops form based on this compound. One of the stages of pharmaceutical research is the development of quality control methods for both the pharmaceutical substance and the finished dosage form. We have developed a chromatographic separation procedure, which can be used for quality control of active pharmaceutical substance by quantification indicators. We also determined the impurity profile, i.e. the structure of the impurities found in the reaction product of compound B016.